首页|加味生脉方改善模拟急进高原大鼠血气和心肌损伤及机制探索

加味生脉方改善模拟急进高原大鼠血气和心肌损伤及机制探索

扫码查看
目的:基于网络药理学和动物实验,探讨加味生脉方治疗急性高原病(acute mountain sickness,AMS)大鼠的药理作用及机制。方法:在TCMSP、ETCM、GeneCards、DisGenet数据库分别检索加味生脉方的主要活性成分与靶点,AMS疾病靶点。运用STRING数据库进行蛋白质相互作用分析,借助David平台进行基因本体GO功能富集分析和KEGG通路富集分析。对大鼠进行预防给药7 d,再将大鼠置于低压氧舱中,构建急性高原病大鼠模型,检测大鼠的血气指标、白细胞(WBC)数量、炎症指标、氧化应激指标、心肌酶谱、心肌损伤标志物和心肌线粒体酶活性;用蛋白印迹法检测大鼠心肌组织中相关通路的表达。结果:加味生脉方筛选出62个活性成分,主要有苯代南蛇碱、阿朴天仙子碱、灌木远志酮A、高丽槐素等,与AMS筛选出66个共同作用靶点,核心靶点包括ESR1、CA2、EGFR、CA1、MAPK14等;GO富集在BP中主要体现为丝裂原活化蛋白激酶调控和一氧化氮生物合成调控等;MF主要体现为受体复合物和溶酶体等;CC主要体现为类固醇和蛋白磷酸酶等;KEGG富集发现HIF-1、AGE-RAGE等信号通路能在加味生脉方治疗急性高原病中起重要作用。动物实验结果显示,与正常对照组相比,模型对照组血液中血气指标显著降低,血清中炎症因子、心肌酶谱和心肌损伤标志物含量明显升高(P<0。05或P<0。01),心肌组织中氧化应激水平显著升高,线粒体呼吸链酶活性显著降低,P53、HIF-1α蛋白表达明显上调(P<0。05);与模型对照组相比,加味生脉方显著提高血气指标检测值,降低炎症因子和氧化应激水平、心肌酶谱和心肌损伤标志物含量(P<0。01),显著提高心肌线粒体呼吸链酶活性,下调心肌组织中P53、HIF-1α蛋白表达,上调BCL2蛋白表达(P<0。01)。结论:加味生脉方能改善急性高原病大鼠血气指标,降低炎症因子水平,缓解心肌损伤,其作用机制可能与调节P53/HIF-1α/BCL2途径有关。
Improvement of Blood Gas and Myocardial Injury in Rats with Simulated Acute Mountain Sickness by Modified Shengmai(生脉)Formula and Exploration of Its Mechanism
Objective:Based on network pharmacology and animal experiments,this study aimed to explore the pharmacological effects and mecha-nisms of Modified Shengmai(生脉)formula(MSMF)in treating rats with acute mountain sickness(AMS).Methods:Active ingredients and targets of MSMF as well as the targets related to AMS were searched in TCMSP,ETCM,GeneCards,and DisGenet databases.Protein-pro-tein interaction analysis was conducted using the STRING database.Gene ontology(GO)functional enrichment analysis and KEGG pathway enrichment analysis were carried out using the DAVID platform.AMS models were created through simulated high-altitude hypoxia after seven days of drug treatment.Various indicators including blood gas,white blood cell(WBC)counts,inflammation markers,oxidative stress mark-ers,myocardial enzymes,myocardial injury markers,and myocardial mitochondrial enzyme activity were measured.The expressions of the pro-teins of relevant pathways in rat myocardial tissues were also detected using Western blotting.Results:Sixty-two active components were iden-tified in MSMF,including Celabenzine,Aposiopolamine,Frutinone and AInermin.These components were found to interact with 66 common targets related to AMS,with core targets including ESR1,CA2,EGFR,CA1,and MAPK14.GO enrichment analysis showed that in Biological Process(BP),the formula primarily regulated processes like mitogen-activated protein kinase and nitric oxide biosynthetic control.Molecular function(MF)enrichment highlighted functions related to receptor complexes and lysosomes,while Cellular Component(CC)primarily showed steroids and protein phosphatases.KEGG analysis revealed the involvement of signaling pathways such as HIF-1 and AGE-RAGE in the therapeutic effect of MSMF on AMS.Animal experiment results showed that compared with control group,model group had significantly re-duced blood gas indicators(P<0.05)and significantly elevated indexes of inflammatory factors,myocardial enzyme spectrum,and biomarkers of myocardial injury(P<0.01).In myocardial tissue,the level of oxidative stress was significant increased and mitochondrial respiratory chain enzyme activity was significantly decreased(P<0.01).The protein expressions of P53 and HIF-1α were up-regulated and BCL2 expression was down-regulated(P<0.05).Compared with model group,treatment with MSMF significantly improved blood gas indicator levels(P<0.05),reduced inflammatory factors and oxidative stress levels,decreased myocardial enzyme spectrum and myocardial injury marker levels(P<0.01),significantly increased mitochondrial respiratory chain enzyme activity,and lowered protein expression levels of P53 and HIF-1αin myocardial tissue(P<0.05),with a significant increase in BCL2 protein expression.Conclusion:MSMF improves blood gas parameters,alleviates inflammation and relieves myocardial injury in rats with AMS.The mechanism may be related to the regulation of the P53/HIF-1α/BCL2 pathway.

Modified Shengmai(生脉)formulaAcute mountain sicknessNetwork pharmacologyMyocardial damageOxidative pressureInflammatory factor

李方扬、党万云、张程、伍振辉、茹毅、高熔、吴香军、王一豪、李茂星、王宇光、高月

展开 >

广东药科大学药学院,广州 510006

军事医学研究院辐射医学研究所,北京 100850

加味生脉方 急性高原病 网络药理学 心肌损伤 氧化应激 炎症因子

2024

中药药理与临床
中国药理学会 四川省中医药科学院

中药药理与临床

北大核心
影响因子:0.996
ISSN:1001-859X
年,卷(期):2024.40(11)